IL-2(rHUIL-2) AS CONSOLIDATION IMMUNOTHERAPY AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR HIGH-RISK NEUROBLASTOMA (HR-NB)